Return to Clinical Trials Search Results

KCP-330-024: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER

Primary Outcome Measures : Progression Free Survival (PFS) [ Time Frame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled) ] Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Primary Outcome Measures : Progression Free Survival (PFS) [ Time Frame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled) ] Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.